蒲公英 - 制药技术的传播者 GMP理论的实践者

搜索
查看: 302|回复: 7
收起左侧

[文献互助] 求助-Baseline Guide Volume 7: Risk-Based Manufacture of Pharma Products,2nd

[复制链接]
发表于 2021-10-29 08:13:53 | 显示全部楼层 |阅读模式

欢迎您注册蒲公英

您需要 登录 才可以下载或查看,没有帐号?立即注册

x
求助此文件,谢谢!可用教材或其他文件交换(如果我有)
邮箱:buzhou-wys@163.com

https://guidance-docs.ispe.org/Baseline-Guide-Volume-7-Risk-Based-Manufacture-of-Pharma-Products
Author(s): Naumann, Bruce D., PhD, DABT; Wilkins, Stephanie A.; Dolgin, David D.; Forsyth, Richard; Goldschmidt, Norman A.; Shamez, Rizwan, PhD
The ISPE Baseline® Guide: Risk-Based Manufacture of Pharmaceutical Products (Risk-MaPP) Second Edition provides a scientific risk-based approach, based on ICH Q9 Quality Risk Management, for managing the risk of cross-contamination within shared facilities. Risk management processes should be used to determine and document reasonable and acceptable risk, in order to maintain product quality and operator safety and to satisfy regulatory requirements.
The ISPE Baseline® Guide: Risk-Based Manufacture of Pharmaceutical Products (Risk-MaPP) Second Edition provides a process that allows manufacturers to assess risk and determine where control strategies are necessary to meet acceptable limits for cross-contamination. The control strategies to manage risk can vary from administrative to full dedication or segregation. Typically, some combination of control strategies may be necessary. This Guide is intended to provide a consistent approach on setting acceptable limits to assess the potential of cross-contamination, thus enabling implementation of appropriate controls to facilitate safe and affordable drug product manufacturing.
The revision to the ISPE Baseline® Guide: Risk-Based Manufacture of Pharmaceutical Products (Risk-MaPP) Second Edition acknowledges that the overall principles presented in the first edition are still valid, but includes several changes to support ongoing developments:
  • Information has been added to support significant changes in regulations and the application of regulations. These include:
  • Updated EU GMPs relative to the use of quality risk management principles in managing the risk of cross-contamination.
  • EMA issued guideline on setting Health Based Exposure Limits (HBELs) for use in the risk management process for shared facilities. This guidance also states that PDE [Permitted Daily Exposure] and ADE [Allowable Daily Exposure] are effectively synonymous.
  • ICH issued M7 guideline “Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk”, which sets a Threshold of Toxicological Concern (TTC) for mutagenic impurities in drug substances and drug products when there is insufficient data to calculate the acceptable limit.
  • Adoption by U.S. and EU regulators of a lifecycle approach to process validation incorporating three stages of process design, process qualification, and continued process verification. The process validation lifecycle approach recognizes that validation is an ongoing control strategy to manage risks and maintain process control. The concept of ongoing assurance of cleaning process efficacy is one of the keys to the control of cross-contamination outlined in this guide.
  • Implementation of risk-based approaches to managing the risk of cross-contamination and sharing lessons learned.
  • Information has been relocated, so that the layout of the Guide aligns with the ICH Q9 process.
  • Updated application example has been added, based on an increased understanding and more experience with Quality Risk Management, and more specifically with risk assessments for cross-contamination.


回复

使用道具 举报

药徒
发表于 2021-10-29 08:57:23 | 显示全部楼层
在博普智库花5元钱可以下载
回复

使用道具 举报

 楼主| 发表于 2021-10-29 09:43:44 | 显示全部楼层
我是QA刘 发表于 2021-10-29 08:57
在博普智库花5元钱可以下载

谢谢  这就是试试
回复

使用道具 举报

 楼主| 发表于 2021-10-29 09:47:20 | 显示全部楼层
我是QA刘 发表于 2021-10-29 08:57
在博普智库花5元钱可以下载

去看了下,不是完整版本,大约缺了60页左右

点评

你通过一下我的好友申请,或者咱们用邮箱私聊一下可以吗?  详情 回复 发表于 2021-10-29 09:54
是吗?哦哦好吧。  详情 回复 发表于 2021-10-29 09:48
回复

使用道具 举报

药徒
发表于 2021-10-29 09:48:58 | 显示全部楼层
1949stone 发表于 2021-10-29 09:47
去看了下,不是完整版本,大约缺了60页左右

是吗?哦哦好吧。
回复

使用道具 举报

药徒
发表于 2021-10-29 09:54:34 | 显示全部楼层
1949stone 发表于 2021-10-29 09:47
去看了下,不是完整版本,大约缺了60页左右

你通过一下我的好友申请,或者咱们用邮箱私聊一下可以吗?
回复

使用道具 举报

 楼主| 发表于 2021-10-29 09:55:33 | 显示全部楼层

不知道是不是那个论坛就显示这么多页  我留言问一下  要是全的就好了  也希望是全本
谢谢您提供的的资讯

点评

我这儿有全版的,咱们互换吧,正好我也缺几个指南。  详情 回复 发表于 2021-10-29 10:01
回复

使用道具 举报

药徒
发表于 2021-10-29 10:01:23 | 显示全部楼层
1949stone 发表于 2021-10-29 09:55
不知道是不是那个论坛就显示这么多页  我留言问一下  要是全的就好了  也希望是全本
谢谢您提供的的资 ...

我这儿有全版的,咱们互换吧,正好我也缺几个指南。你查看下你的邮箱。
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

×发帖声明
1、本站为技术交流论坛,发帖的内容具有互动属性。您在本站发布的内容:
①在无人回复的情况下,可以通过自助删帖功能随时删除(自助删帖功能关闭期间,可以联系管理员微信:8542508 处理。)
②在有人回复和讨论的情况下,主题帖和回复内容已构成一个不可分割的整体,您将不能直接删除该帖。
2、禁止发布任何涉政、涉黄赌毒及其他违反国家相关法律、法规、及本站版规的内容,详情请参阅《蒲公英论坛总版规》。
3、您在本站发表、转载的任何作品仅代表您个人观点,不代表本站观点。不要盗用有版权要求的作品,转贴请注明来源,否则文责自负。
4、请认真阅读上述条款,您发帖即代表接受上述条款。

关闭

站长推荐上一条 /1 下一条

QQ|手机版|蒲公英|ouryao|蒲公英 ( (京)-非经营性-2014-0058 京ICP证150354号 京ICP备14042168号-1 )

GMT+8, 2024-5-16 02:09

Powered by Discuz! X3.4运维单位:苏州豚鼠科技有限公司

Copyright © 2001-2020, Tencent Cloud.

声明:蒲公英网站所涉及的原创文章、文字内容、视频图片及首发资料,版权归作者及蒲公英网站所有,转载要在显著位置标明来源“蒲公英”;禁止任何形式的商业用途。违反上述声明的,本站及作者将追究法律责任。
快速回复 返回顶部 返回列表